OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Germany is a mature market with high healthcare expenditure and pharmaceutical production but future growth could be potentially hindered by cost-saving government policies.
The pharmaceutical market in Germany is valued at $58.6 billion in 2014, according to research and consulting firm GlobalData. Despite its position as the leading pharmaceutical market in Europe, the sector is projected to expand at a modest compound annual growth rate (CAGR) of 1.7% to reach an estimated $65 billion by 2020.
A new GlobalData report notes that Germany is a mature market with high healthcare expenditure and pharmaceutical production but future growth could be potentially hindered by cost-saving government policies. Arzneimittelmarkt-Neuordnungsgesetz (AMNOG), for example, was introduced by the German government in 2011 to control the increasing drug expenditure within the public health sector. Drug manufacturers, however, have not approved of the new measures introduced by this law.
Prior to the enactment of AMNOG in Germany, there were very few limitations to the drug pricing of new or patented products, and this was one of the main reasons for the increasing healthcare expenditure, commented Joshua Owide, GlobalData’s director of healthcare industry dynamics in a press statement. “AMNOG features an early benefit assessment for newly registered medicinal products, whereby drugs with no additional benefit are placed on the reference pricing system, which fixes a maximum reimbursement limit for groups of comparable treatments. For drugs with added benefits, prices can be negotiated with their manufacturers.”
In the report, GlobalData highlighted that these measures are further exacerbated by government-imposed price freezes and reductions on pharmaceuticals, a large market for generic products and the exclusion of several drug categories by Statutory Health Insurance (SHI).
Owide observed that patients are often unwilling to opt for drugs that are not reimbursed by SHI funds and this has an effect on the market for those products. “Furthermore, according to Federal Health Reporting, the German generic market is the largest in the EU, accounting for approximately 73.5% by volume and 33.1% by value of Germany’s total pharmaceutical sales in 2013. This tendency to favor generics may restrict future sales of patented drugs.”